Home › Companies › ENTRADA THERAPEUTICS INC. › 2024-2025
At ENTRADA THERAPEUTICS INC.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 51 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 561 separate fund positions. On the most widely held item on that ballot — Election of Directors: Dipal Doshi — FOR was 98% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ENTRADA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ENTRADA THERAPEUTICS INC.’s Form 8-K, filed June 11, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 11, 2025: 4 items on ENTRADA THERAPEUTICS INC.’s Form 8-K, filed June 11, 2025: 1 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025
Explore ENTRADA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ENTRADA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dipal Doshi | 27,809,399 | -- | -- | 429,248 | 2,020,879 | 98% | Not verified | — |
| Elect Director: Kush M. Parmar, M.D., Ph.D. | 24,883,797 | -- | -- | 3,354,850 | 2,020,879 | 88% | Not verified | — |
| Elect Director: Mary Thistle | 27,768,093 | -- | -- | 470,554 | 2,020,879 | 98% | Not verified | — |
| 2. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 30,176,125 | 74,925 | 8,476 | -- | -- | 99.7% | Approved | — |
Source: ENTRADA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 11, 2025 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a ENTRADA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Dipal Doshi
ENTRADA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dipal Doshi”): 27,809,399 for, 429,248 withheld, per its Form 8-K filed June 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 6,537,113 for, 98,270 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,795,121 | 0 | 0 | 0 | For |
| Vanguard | 1,546,027 | 0 | 0 | 0 | For |
| Fidelity | 1,104,057 | 0 | 0 | 0 | For |
| BlackRock | 919,946 | 0 | 0 | 0 | For |
| Charles Schwab | 193,837 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 94,534 | Withhold |
| Federated Hermes | 94,074 | 0 | 0 | 0 | For |
| MFS | 88,732 | 0 | 0 | 0 | For |
| Northern Trust | 79,332 | 0 | 0 | 0 | For |
| First Trust | 75,816 | 0 | 0 | 0 | For |
| American Century | 68,661 | 0 | 0 | 0 | For |
| Equitable | 65,206 | 0 | 0 | 0 | For |
| TIAA | 62,313 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,607 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 40,616 | 0 | 0 | 0 | For |
| Nationwide | 34,190 | 0 | 0 | 0 | For |
| SEI | 33,702 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,290 | 0 | 0 | 0 | For |
| WisdomTree | 28,985 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 21,300 | 0 | 0 | 0 | For |
| John Hancock | 21,005 | 0 | 0 | 0 | For |
| Goldman Sachs | 19,820 | 0 | 0 | 0 | For |
| GuideStone | 16,724 | 0 | 0 | 0 | For |
| Global X | 14,527 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 14,335 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Kush M. Parmar, M.D., Ph.D.
ENTRADA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kush M. Parmar, M.D., Ph.D.”): 24,883,797 for, 3,354,850 withheld, per its Form 8-K filed June 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 6,000,067 for, 635,316 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,795,121 | 0 | 0 | 0 | For |
| Vanguard | 1,546,027 | 0 | 0 | 0 | For |
| Fidelity | 1,104,057 | 0 | 0 | 0 | For |
| BlackRock | 919,946 | 0 | 0 | 0 | For |
| Charles Schwab | 193,837 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 94,534 | Withhold |
| Federated Hermes | 94,074 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 88,732 | Withhold |
| Northern Trust | 0 | 0 | 0 | 79,332 | Withhold |
| First Trust | 0 | 0 | 0 | 75,816 | Withhold |
| American Century | 0 | 0 | 0 | 68,661 | Withhold |
| Equitable | 51,446 | 0 | 0 | 13,760 | Mixed |
| TIAA | 62,313 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,607 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 40,616 | 0 | 0 | 0 | For |
| Nationwide | 1,159 | 0 | 0 | 33,031 | Withhold |
| SEI | 33,702 | 0 | 0 | 0 | For |
| Lincoln Financial | 18,300 | 0 | 0 | 11,990 | Mixed |
| WisdomTree | 0 | 0 | 0 | 28,985 | Withhold |
| TARGET PORTFOLIO TRUST | 21,300 | 0 | 0 | 0 | For |
| John Hancock | 11,625 | 0 | 0 | 9,380 | Mixed |
| Goldman Sachs | 0 | 0 | 0 | 19,820 | Withhold |
| GuideStone | 0 | 0 | 0 | 16,724 | Withhold |
| Global X | 14,527 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 14,335 | Withhold |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Mary Thistle
ENTRADA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Thistle”): 27,768,093 for, 470,554 withheld, per its Form 8-K filed June 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 6,537,113 for, 98,270 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,795,121 | 0 | 0 | 0 | For |
| Vanguard | 1,546,027 | 0 | 0 | 0 | For |
| Fidelity | 1,104,057 | 0 | 0 | 0 | For |
| BlackRock | 919,946 | 0 | 0 | 0 | For |
| Charles Schwab | 193,837 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 94,534 | Withhold |
| Federated Hermes | 94,074 | 0 | 0 | 0 | For |
| MFS | 88,732 | 0 | 0 | 0 | For |
| Northern Trust | 79,332 | 0 | 0 | 0 | For |
| First Trust | 75,816 | 0 | 0 | 0 | For |
| American Century | 68,661 | 0 | 0 | 0 | For |
| Equitable | 65,206 | 0 | 0 | 0 | For |
| TIAA | 62,313 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,607 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 40,616 | 0 | 0 | 0 | For |
| Nationwide | 34,190 | 0 | 0 | 0 | For |
| SEI | 33,702 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,290 | 0 | 0 | 0 | For |
| WisdomTree | 28,985 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 21,300 | 0 | 0 | 0 | For |
| John Hancock | 21,005 | 0 | 0 | 0 | For |
| Goldman Sachs | 19,820 | 0 | 0 | 0 | For |
| GuideStone | 16,724 | 0 | 0 | 0 | For |
| Global X | 14,527 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 14,335 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
ENTRADA THERAPEUTICS INC.’s own tally for this item (“2. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 30,176,125 for, 74,925 against — passed, per its Form 8-K filed June 11, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 6,635,383 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,795,121 | 0 | 0 | 0 | For |
| Vanguard | 1,546,027 | 0 | 0 | 0 | For |
| Fidelity | 1,104,057 | 0 | 0 | 0 | For |
| BlackRock | 919,946 | 0 | 0 | 0 | For |
| Charles Schwab | 193,837 | 0 | 0 | 0 | For |
| Dimensional | 94,534 | 0 | 0 | 0 | For |
| Federated Hermes | 94,074 | 0 | 0 | 0 | For |
| MFS | 88,732 | 0 | 0 | 0 | For |
| Northern Trust | 79,332 | 0 | 0 | 0 | For |
| First Trust | 75,816 | 0 | 0 | 0 | For |
| American Century | 68,661 | 0 | 0 | 0 | For |
| Equitable | 65,206 | 0 | 0 | 0 | For |
| TIAA | 62,313 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,607 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 40,616 | 0 | 0 | 0 | For |
| Nationwide | 34,190 | 0 | 0 | 0 | For |
| SEI | 33,702 | 0 | 0 | 0 | For |
| Lincoln Financial | 30,290 | 0 | 0 | 0 | For |
| WisdomTree | 28,985 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 21,300 | 0 | 0 | 0 | For |
| John Hancock | 21,005 | 0 | 0 | 0 | For |
| Goldman Sachs | 19,820 | 0 | 0 | 0 | For |
| GuideStone | 16,724 | 0 | 0 | 0 | For |
| Global X | 14,527 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 14,335 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 37,953,417 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 4.73% |
| 2 | Vanguard | 4.07% |
| 3 | Fidelity | 2.91% |
| 4 | BlackRock | 2.42% |
| 5 | Charles Schwab | 0.51% |
| 6 | Dimensional | 0.25% |
| 7 | Federated Hermes | 0.25% |
| 8 | MFS | 0.23% |
| 9 | Northern Trust | 0.21% |
| 10 | First Trust | 0.20% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Baker Bros. Advisors LP | 21.69% | DEF14A |
| Entities affiliated with 5AM Ventures | 11.62% | DEF14A |
| Entities affiliated with MPM Capital | 11.54% | DEF14A |
| Andrew J. Schwab | 10.69% | 13D |
| T. Rowe Price | 7.21% | 13F |
| Roche Finance Ltd | 6.77% | 13G |
| BlackRock | 5.25% | 13F |
| TCG Crossover GP I, LLC | 5.05% | 13G |
| Dipal Doshi, Chief Executive Officer and Director | 4.20% | DEF14A |
| Vanguard Group | 4.15% | 13F |
Percentages above are of 37,953,417 shares outstanding, as reported by ENTRADA THERAPEUTICS INC. on its Form 10-Q dated April 30, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ENTRADA THERAPEUTICS INC.’s 10-Q dated April 30, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ENTRADA THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page).
proxyvotesnow.com, “ENTRADA THERAPEUTICS (TRDA) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/entrada-therapeutics-inc/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.